Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient (BIOCOVU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04341792|
Recruitment Status : Recruiting
First Posted : April 10, 2020
Last Update Posted : September 25, 2020
There is no predictive tool for patients admitted to the emergency department with a suspicion of Covid-19 that will worsen secondarily and require a heavy lifting.
In a context of saturation of the healthcare system by the pandemic at Covid-19,it is essential to identify specific, accessible prognostic markers via minimally invasive sampling with low risk of infection for personnel caregiver, for optimal allocation of resuscitation resources.
This study proposes to evaluate the biological markers of routine care known to be associated with resuscitation admission in relation to hospitalization on conventional service for the prediction of worsening of patients admitted to the emergencies for Covid-19.
|Condition or disease|
|Infection Viral Coronavirus COVID-19|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic|
|Actual Study Start Date :||April 11, 2020|
|Estimated Primary Completion Date :||April 2021|
|Estimated Study Completion Date :||April 2021|
- Rate of secondary aggravation [ Time Frame: an average at 30 days (- 2 days +3 days) of admission to the emergency department ]
Secondary aggravation is defined as :
- a re-hospitalization or
- aggravation in hospitalization : development or increase in oxygen dependency, hemodynamic failure, and/or respiratory, death
- Change of standart biological parameters [ Time Frame: Between baseline and an average at 30 days (- 2 days +3 days) of admission to the emergency department ]the number of leukocytes, lymphocytes, neutrophil polynuclear cells, CRP, fibrinogen, and the D-dimers.
- Change of Von willebrand factor (vWF) changes over time [ Time Frame: Between baseline and an average at 30 days (- 2 days +3 days) of admission to the emergency department ]
- Change of the Factor VIII (FVIII) [ Time Frame: Between baseline and an average at 30 days (- 2 days +3 days) of admission to the emergency department ]
- Prevalence of positivity of COVID-19 virus measured by PCR or serology [ Time Frame: an average at 30 days (- 2 days +3 days) of admission to the emergency department ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04341792
|Contact: Delphine Garrigue, MD||03 20 44 67 97 ext +33||Delphine.firstname.lastname@example.org|
|Hôpital Roger Salengro, CHU Lille||Recruiting|
|Lille, France, 59037|
|Principal Investigator: Delphine Garrigue, MD,PhD|
|Principal Investigator:||Delphine Garrigue, MD||University Hospital, Lille|